Sentences with phrase «stock at a discounted rate»

Both investors and companies tend to adore DRIPs — investors, because they're an easy way of acquiring stock without having to pay any broker's fees (and DRIPs also spare you the temptation of blowing your dividends on sneakers and tasting menus) Companies like offering DRIPs because they can disperse dividends without having to actually use cash, and because of that, many companies will offer stock at a discounted rate to those enrolled in DRIPs.

Stock Investment Plan — provides employees with the opportunity to purchase Franklin Resources, Inc. (BEN) common stock at a discounted rate

Employee stock purchase plans allow for plan participants to purchase company stock at a discounted rate of up to 15 % (subject to your specific plan rules, of course).

Stock Investment Plan — provides employees with the opportunity to purchase Franklin Resources, Inc. (BEN) common stock at a discounted rate

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The technology provider also offers a stock purchase plan that offers employees the opportunity to buy and sell stock every six months at a discounted rate of 15 %.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Our accounting for acquisitions involves significant judgments and estimates, including the fair value of certain forms of consideration such as our common stock, preferred stock or warrants, the fair value of acquired intangible assets, which involve projections of future revenues, cash flows and terminal value which are then discounted at an estimated discount rate, the fair value of other acquired assets and assumed liabilities, including potential contingencies, and the useful lives of the assets.

At current levels of rates and risk premiums, a mere 1 % increase in the discount rate (from 4.7 % to 5.7 %) would shave nearly 4 P / E points off the stock market's fair value on a trailing earnings basis.

Shopbop is the place to stock up on designer items year round, but when they put on sales (only a few times a year), it's a golden opportunity to get high ticket items at a discounted rate (which really never happens)!

So it appears that if, in my example above, the taxpayer exercises his option to buy a $ 60 stock for $ 40, that $ 20 discount will be taxed at ordinary income rates if he immediately sells the stock.

If dividends are discounted at a higher rate, stock prices should come down, other things equal.

The fact that interest rates looks to be rising combined with the opinion that value stocks are trading at a discount to the market, has convinced the Chief Portfolio Manager that there is a favorable environment for value investing.

Value stocks» outperformance is even more pronounced for small and mid cap companies, because they tend to trade at even bigger discounts due to illiquidity and lack of analyst coverage, as well as being able to achieve higher growth rates than larger companies.

As a stock investor, you could go the mutual fund route with great names like Vanguard, Fidelity, Charles Schwab, and T. Rowe Price, but to add some flexibility to your portfolio at really affordable transaction rates, you may also be interested in signing up with an online discount broker.

«Exercising» your stock options literally means buying your stock, so the sooner you exercise, the sooner you can sell your stock at a discounted tax rate.

That is, R = the long - term stock market return (with dividends reinvested) if and only if dividends can be reinvested at the same discount rate.

If I receive ESPP at a discounted rate, but do not sell the stocks, hence making no profit, do I need to claim them on my Canadian taxes?

Sayaji takes comfort and personalized service to the highest levelGrande Seventh Features / Amenities Personal Butler for every need Personal Chef for food of choice Personal Jacuzzi in suites Breakfast & bar lounge on the same floor Personal PCs andWi - fi in every roomA special chair in suite Personal Home Theatre, and an LCD in each Convenience of gym on the same floor Check - in and check - out from room Grande Seventh Benz Pick up and DropComputers with InternetButler ServiceMusic on Demand of ChoiceMovie on Demand of Choice Personalized StationaryFull Stock Soft BarTea - Coffee MakerExpress check - in and check - outExclusive Lounge for GrandeChoice of Newspapers and MagazinesExclusive Fitness for Grande GuestsReception on Floor with Floor LoungeJacuzzi & Shower CubiclesLCD and ComputersElectronic LocksIn Room - Safe Deposit LockersCar Hiring - Free car at your disposal on rack tariff or subsidized rate on discount tariffSAYAJI GRANDESayaji Grande, the premium floor at Sayaji, Indore.

If a pack you want is out of stock, go to the side of page under «Other Sellers» and you should be able to place an order on «back order» and receieve it at the discounted rate when Amazon gets another shipment!

Stock of AirPods has been getting snapped up at a super fast rate, which isn't great news for those of you looking for a big discount.

Part time and full time employees are also able to enjoy such perks as a 15 % employee discount, flex pay which assists with paying certain medical expenses, an employee stock purchase, profit sharing, a purchase program, which allows staff to purchase items from vendors set up with Walgreens at discounted rates and career connections, which allows staff to apply for district and corporate level positions.